Focus on digitalization, life sciences and climate protection - part of REACT-EU scheme
The European Commission has approved the use of EUR 30 million in funds for climate protection and innovation funds in Hamburg through 2023 as part of the REACT-EU scheme, the Ministry of Economics announced.
The REACT-EU scheme
The scheme with a total of EUR 47.5 billion aims to build a more sustainable, digital and resilient EU economy in the wake of the pandemic.
Funds for digitalisation, life sciences and climate protection
"I am pleased that we will be able to use these European funds to promote forward-looking projects from which Hamburg and its residents will benefit far beyond the end of the funding period," said Michael Westhagemann, Senator for Economics. The funds will go towards projects focusing on the intelligent use of energy in companies and will be available as venture capital for innovative startups. Funds will also be made available for life sciences, infection, pandemic control, and digitization.
Funds to strengthen Hamburg
"Important issues in future, from digitalisation to climate protection have lost none of their relevance as a result of the pandemic. At the same time, it is important to expand infection research in Hamburg, especially in view of the knowledge gained during the pandemic" said Katharina Fegebank, Senator for Science, Research and Equality." The EU funds will strengthen Hamburg's diversity and breadth as a centre of innovation in the long term, she added.
More News
Pacira BioSciences Acquires GQ Bio
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT
medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Read more …